An innovative drug delivery system utilizing hydrogel-forming microneedles that undergo programmed mesophase transitions. This technology allows for the controlled release of drugs, enhancing the efficacy and safety of pharmaceutical treatments. The microneedles transition from solid to swollen hydrogel upon contact with biological fluids, followed by further transformation into hydrogel microparticles, which facilitates a sustained release of the active pharmaceutical ingredient (API).

In collaboration with Dr. Aiman Abu Ammar, Department of Pharmaceutical Engineering, Azrieli College of Engineering Jerusalem.

Unmet Need

Current drug delivery methods often face challenges such as poor bioavailability, rapid clearance, and the need for frequent dosing. Traditional delivery systems can lead to suboptimal therapeutic outcomes and patient non-compliance. There is a significant need for advanced delivery systems that can provide controlled and sustained release of drugs, minimizing side effects and improving patient adherence. The ability to deliver drugs transdermally, nasally, or vaginally using microneedles addresses these challenges by offering a less invasive and more efficient route of administration.

Our Solution

The solution involves the use of solid microneedles made from a PEG based tri-block amphiphile . The molecular structure, concentration of the tri-block amphiphile, and addition of excipients can vary widely, allowing for customization based on the specific drug and desired release profile. PEG is particularly advantageous due to its water-solubility, non-toxicity, and favorable physical properties, making it suitable for pharmaceutical applications. This innovative microneedle system enhances drug delivery efficiency and ensures complete clearance of the delivery system post-drug release through enzymatic degradation. So far, the technology has been demonstrated with microneedles containing amphotericin B, which is an antifungal drug. In addition, in vitro release study of dexamethasone (DEX), as a steroid model drug, showed first-order drug release, with 90% released within 6 days.

Market

The market for drug delivery systems is rapidly expanding, driven by the increasing demand for effective and patient-friendly treatment options. The global drug delivery market is projected to grow significantly, with transdermal delivery systems gaining traction due to their convenience and effectiveness. The unique features of the hydrogel-forming microneedles, including their ability to provide controlled release and minimize side effects, position them favorably within this competitive landscape. As healthcare continues to evolve towards personalized medicine, the potential applications of this technology in various therapeutic areas, including vaccines and chronic disease management, present substantial market opportunities.